Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01114139 · ClinicalTrials.gov registry record · Phase 3
A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia
A Phase 3 study, sponsored by AMAG Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 812
- Enrollment target
NCT01114139: Completed Phase 3 study, sponsored by AMAG Pharmaceuticals.
NCT01114139 is a Phase 3 study that has completed, run by AMAG Pharmaceuticals. The registered enrollment target is 812 participants, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01114139, a Phase 3 study, has completed, sponsored by AMAG Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 812 participants
- Enrollment target
Study Summary
To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
Primary Outcome
Participants who achieved a ≥2.0 g/dL increase in hemoglobin at any time from Baseline up to Week 5 are presented. Increase in hemoglobin at any time from Baseline up to Week 5 was calculated for each participant based on: Hemoglobin Change = Hemoglobin (Week X) - Hemoglobin (Baseline), where Week X was any post-Baseline visit up to and including Week 5. Baseline was defined as the Day 1 value (prior to injection of study drug). The screening or most recent value prior to Day 1 was used for an
Interventions
- DRUG Ferumoxytol
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 812 participants |
| Start Date | 2010-06-19 |
| Est. Completion | 2012-10-22 |
| Phase | Phase 3 |
What the finished NCT01114139 record still lists
NCT01114139 is an interventional study that assigns participants to a tested intervention. The registered 812 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which Ferumoxytol is the first listed.
NCT01114139 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01114139 about?
NCT01114139 is a clinical study titled "A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia". To evaluate the efficacy and safety of intravenous (IV) ferumoxytol compared with placebo for the treatment of iron deficiency anemia (IDA).
What is the current status of trial NCT01114139?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 812 participants. The study started on 2010-06-19. Estimated completion is 2012-10-22.
What interventions are being tested in trial NCT01114139?
The interventions under investigation include: Ferumoxytol (DRUG), Placebo (OTHER).
Who is sponsoring clinical trial NCT01114139?
This trial is sponsored by AMAG Pharmaceuticals, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01114139's enrollment target sits among peer trials
812 408th of 2000 higher than 1,593 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05519085 · 810 participants · Phase 3
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
- NCT07218029 · 815 participants · Phase 3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
- NCT06529094 · 808 participants · NA
Implementing a Decision Support Tool to Prevent Community-Acquired Pressure Injury in Spinal Cord Injury (SCI) in the Spinal Cord Injury Clinic
- NCT04846959 · 818 participants
Study to Evaluate Pregnancy Outcomes in Risankizumab Exposed Pregnancies Relative to Those Non-risankizumab Exposed Pregnancies in Women With FDA Approved Indications
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI